TreeFrog Therapeutics SAS announced that it will entered into a purchase agreement for gross proceeds of $25 million on April 23, 2024. The transaction include the participation from new investor Vertex Pharmaceuticals Incorporated. The company will issue common shares in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
418.8 USD | +2.09% | +4.15% | +2.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.93% | 108B | |
+7.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B | |
-24.02% | 8.32B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- TreeFrog Therapeutics SAS announced that it expects to receive $25 million in funding from Vertex Pharmaceuticals Incorporated